Hematological Malignancies In the News
City of Hope is now enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor (CAR) T cell therapy trial. It will also manufacture CAR T cells in its own laboratories.
City of Hope doctors have performed more than 250 haploidentical stem cell transplants in the last five years. They are giving more and more patients a new treatment option.
City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.
Scientist Defu Zeng is tackling graft-versus-host disease, a common side effect of bone marrow transplants, taking several tacks that include modulating T cells and fine-tuning specific proteins and antibodies.
Where in the early days of the HIV epidemic the idea of stem cell transplants for HIV patients with cancer was considered crazy, the procedure is now commonly performed.
Provost and Chief Scientific Officer Steven T. Rosen, M.D., the Irell & Manella Cancer Center Director’s Distinguished Chair, has been inducted as a member of the Association of American Physicians (AAP). Membership to the AAP is bestowed upon those physicians who indicate a "pre-eminence and the highest caliber of physician-led science accomplishments and scientific leadership."
City of Hope opens recruitment for a phase I/II dose-finding study of novel agent 8-chloro-adenosine in patients with relapsed/refractory acute myeloid leukemia.
City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.
City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.
Jianjun Chen, Ph.D., has been named the Simms/Mann Family Foundation Chair in Systems Biology at City of Hope in recognition of his leading-edge research that is helping to build the foundation of personalized, gene-based medicine.
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research (AACR) annual meeting from March 29 through April 3 in Atlanta.
City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma (CTCL).
In the first reported case of its kind, gluteal implants have been linked to a rare form of cancer that ultimately led to a woman’s death.
Stephen J. Forman, M.D., the renowned leader of the Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, will receive the 2019 DKMS Mechtild Harf Science Award in honor of his outstanding achievements in cancer immunology, hematology, stem cell transplantation and CAR T cell therapy.
City of Hope has long been renowned for its expertise in treating cancer and diabetes. But specialists here also are tackling lesser-known but equally devastating diseases that may or may not have an oncologic component.
City of Hope has earned its third Lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute, which provides $12.5 million for research.
An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI), one of four current NCI-supported lymphoma SPOREs. The grant covers a five-year period and totals $12.5 million.
Vanessa Jonsson, Ph.D., focuses on chimeric antigen receptor (CAR) T cell therapy. Using such tools as computational analysis and mathematical modeling, she examines the complex interactions between the tumor, the patient’s immune system and the therapy to learn how the tumor evades the immune response.
What's it like to work at the center of a true medical and scientific revolution? It's emotional, often overwhelming. But it’s also a place to witness miracles. Such is the life of the clinical research nurses who staff City of Hope's CAR T cell program.
Meet float rider Cheryl Wiers, a wife and mother of two who battled cancer twice only to have it return. She eventually found prolonged remission thanks to a CAR T Cell therapy offered at City of Hope.
Meet City of Hope 2019 Rose Parade float rider Olivia Gaines, an aspiring songwriter and amateur pianist who has witnessed how music speaks to the heart and calms spirits.
City of Hope clinical and laboratory investigators presented leading-edge research, including new targets in CAR T cell therapy, at the 60th annual ASH meeting in San Diego.
Seven City of Hope patients will welcome the New Year atop City of Hope’s 47th Rose Parade float, “Harmony of Hope.” Meet float rider Abraham Laboriel, a world-renowned bassist whose work has been featured in 4,000 recordings and film soundtracks, including “Coco,” “Frozen” and “Incredibles 2.”
Xiuli Wang, Ph.D., research professor at City of Hope, presented encouraging research on using CAR T cell therapy for central nervous system lymphoma at this year's American Society of Hematology conference.